trebananib

Trebananib is a recombinant peptide-Fc fusion protein (peptibody) developed as an antiangiogenic agent for cancer therapy. It functions by binding to angiopoietin-1 and angiopoietin-2, thereby inhibiting their interaction with the Tie2 tyrosine kinase receptor on endothelial cells. This blockade disrupts angiogenesis and lymphangiogenesis, processes critical for tumor growth and metastasis. Trebananib was primarily investigated in ovarian cancer, peritoneal cancer, fallopian tube cancer, and other solid tumors. Despite showing improvement in progression-free survival in some trials (notably TRINOVA-1), it did not demonstrate a significant overall survival benefit and development has been discontinued for all indications[1][3][5][6].

Other names

trebananib (genetical recombination)Tovasanib